Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Rowe M, et al. Among authors: perl a. Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14371. Online ahead of print. Eur J Haematol. 2024. PMID: 39726154
Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts.
Rudman-Melnick V, Vanhoutte D, Stowers K, Sargent M, Adam M, Ma Q, Perl AKT, Miethke AG, Burg A, Shi T, Hildeman DA, Woodle ESS, Kofron JM, Devarajan P. Rudman-Melnick V, et al. Among authors: perl akt. Sci Rep. 2024 Nov 26;14(1):29307. doi: 10.1038/s41598-024-80930-0. Sci Rep. 2024. PMID: 39592775 Free PMC article.
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.
Brown FC, Wang X, Birkinshaw R, Chua CC, Morley T, Kasapgil S, Pomilio G, Blombery P, Huang DCS, Czabotar P, Priore SF, Yang G, Carroll M, Wei AH, Perl AE. Brown FC, et al. Among authors: perl ae. Blood Adv. 2025 Jan 14;9(1):127-131. doi: 10.1182/bloodadvances.2024014446. Blood Adv. 2025. PMID: 39374584 No abstract available.
Cytokine-mediated CAR T therapy resistance in AML.
Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Bhagwat AS, et al. Among authors: perl ae. Nat Med. 2024 Dec;30(12):3697-3708. doi: 10.1038/s41591-024-03271-5. Epub 2024 Sep 27. Nat Med. 2024. PMID: 39333315 Clinical Trial.
Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia.
Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, May-Zhang AA, Smithers T, Agam Y, Wang Q, Dai HP, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. Peretz CAC, et al. Among authors: perl ae. Nat Commun. 2024 Sep 18;15(1):8191. doi: 10.1038/s41467-024-52317-2. Nat Commun. 2024. PMID: 39294124 Free PMC article.
Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts.
Rudman-Melnick V, Vanhoutte D, Stowers K, Sargent M, Adam M, Ma Q, Perl AKT, Miethke AG, Burg A, Shi T, Hildeman DA, Woodle ESS, Kofron JM, Devarajan P. Rudman-Melnick V, et al. Among authors: perl akt. Res Sq [Preprint]. 2024 Aug 17:rs.3.rs-4746078. doi: 10.21203/rs.3.rs-4746078/v1. Res Sq. 2024. Update in: Sci Rep. 2024 Nov 26;14(1):29307. doi: 10.1038/s41598-024-80930-0 PMID: 39184103 Free PMC article. Updated. Preprint.
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.
Hamilton BK, Pandya BJ, Ivanescu C, Elsouda D, Hamadani M, Chen YB, Levis MJ, Ueda Oshima M, Litzow MR, Soiffer RJ, Ustun C, Perl AE, Singh AK, Geller N, Hasabou N, Rosales M, Cella D, Corredoira L, Pestana C, Horowitz MM, Logan B. Hamilton BK, et al. Among authors: perl ae. Blood Adv. 2024 Oct 8;8(19):5091-5099. doi: 10.1182/bloodadvances.2024013746. Blood Adv. 2024. PMID: 39167766 Free PMC article. Clinical Trial.
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Issa GC, et al. Among authors: perl a. J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9. J Clin Oncol. 2025. PMID: 39121437 Free PMC article. Clinical Trial.
Diversity and Inclusivity in Rheumatology Publications.
Sawalha AH, Allen KD, Feldman CH, Lim SS, Perl A, Solomon DH, Williams EM. Sawalha AH, et al. Among authors: perl a. ACR Open Rheumatol. 2024 Nov;6(11):732-733. doi: 10.1002/acr2.11721. Epub 2024 Aug 1. ACR Open Rheumatol. 2024. PMID: 39090996 Free PMC article. No abstract available.
503 results